Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapyJean‐Marc Kaufman, B. Mitlak, Eric Orwoll et al.|Osteoporosis International|2004Cited by 320
Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter settingThomas Fuerst, B. Mitlak, G.v. Ingersleben et al.|Osteoporosis International|2008Cited by 103
The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosisKristine E. Ensrud, B. Mitlak, Robert R. Recker et al.|ORBi (University of Liège)|1998Cited by 21
Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal womenPD Delmas, H K Genant, KE Ensrud et al.|ORBi (University of Liège)|1999Cited by 4